



Global Fund grants and price reductions

Price reductions in key TB commodities



The Bedaquiline price decrease from **\$289** for a **6-month (6M) course** to **\$130 - \$194** for a treatment course (6M).

Delamanid price decrease from **\$1700** to **\$1190** for a treatment course.



30% price decrease for 3HP (TPT) from **\$15** to approximately **\$10**. (\$9.99 – 10.96)



20% price decrease for Xpert Cartridges taking the Xpert Ultra cartridge from **\$9.98** to **\$7.97**. The agreement also has commitments on **Service & Maintenance**. The Xpert XDR cartridge remains at \$14.90.

Implications for the Global Fund grants

- **Savings should allow for more coverage of these and other TB commodities.**
- **Priority to be given to essential commodities to be moved from PAAR or make up gaps in year 3 coverage**

Grant making and Grant implementation

- All price decreases are valid now.
- PRs wishing to procure the newly reduced commodities are invited to contact their Global Fund Country Team to discuss the most relevant approach to the country/grant context.
- PRs are also invited to contact their Global Fund Country Team or PPM focal point for additional support related to advice around net pricing, bundle pricing, as well as information regarding the Service and Maintenance offering.

**Savings should result in
reducing commodity gaps and
more people on treatment.**



The Global Fund to Fight
AIDS, Tuberculosis and Malaria

+41 58 791 1700
theglobalfund.org